officialstreetpreachers Subscribe
Published: March 1, 2021

COVID-19 jab maker Moderna posts 13-fold revenue increase thanks to vaccine

By The Editor

Big Tech is censoring us. Subscribe to our email list and bookmark LifeSiteNews.com to continue getting our news.  Subscribe now.

March 1, 2021 (LifeSiteNews) — Major COVID-19 vaccine maker Moderna posted a more than 13-fold increase in total revenue in 2020, compared to 2019, the company revealed in an earnings report on Thursday. 

“Total revenue was $803 million for the year ended December 31, 2020 compared to $60 million for the year ended December 31, 2019,” the report said, adding that much of the change is linked to the company’s coronavirus vaccine, mRNA-1273.

“The increases in [the fourth quarter of 2020 and the full year] were driven by increases in grant revenue and product sales,” the report continued. The rise in grant revenue came primarily from an award by the federal Biomedical Advanced Research and Development Authority (BARDA), it said. 

The U.S. government has pledged over $500 million to aid the development of mRNA-1273and claims a stake in the intellectual property, Axios reported last year. Moderna “retains worldwide rights to develop and commercialize” the jab, Thursday’s report noted. 

“We began to recognize revenue in December 2020 from our COVID-19 vaccine subsequent to its authorization for emergency use by the FDA and Health Canada,” the report added, announcing nearly $200

The remainder of this article is available in its entirety at LifeSite News

The views expressed in this news alert by the author do not directly represent that of The Official Street Preachers or its editors


Share this Article

Download the Mobile App.
Exit mobile version